Am J Transplant, Volume 19, Suppl 3 Archives - Page 110 of 214 - ATC Abstracts

2019 American Transplant Congress
Toll Like Receptor 2 Mobilizes Regulatory T Cell Lymphatic Migration by Stimulating Lymphotoxin Expression
W. Piao¹, Y. Xiong², L. Li³, V. Saxena³, C. Paluskievicz³, J. Bromberg⁴
¹Microbiology and Immunology, U. Maryland, Baltimore, baltimore, MD, ²Surgery, U. Maryland, Baltimore, baltimore, MD, ³Surgery, U. Maryland, Baltimore, Baltimore, MD, ⁴Surgery and Microbiology and Immunology, U. Maryland, Baltimore, Baltimore, MD
*Purpose: Regulatory T cell (Treg) afferent lymphatic migration is important for islet allograft survival. Treg express high levels of lymphotoxin (LT) and bind the LT…
2019 American Transplant Congress
Organ Donation Survey among Health Care Professionals in Argentina
V. R. Ruiz¹, A. D. Midley¹, P. E. Rodriguez², S. Bauque², V. Morozovsky¹, A. G. Da lozzo³
¹Respiratory Care, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Organ Procurement, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Lung Trasplant Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
*Purpose: Our objective was to survey health care professionals (HCPs) responsible for the care of potential organ donors (PODs) on attitude toward organ donation, knowledge…
2019 American Transplant Congress
Policy Changes in Facilitated Pancreas Allocation Support Pancreas Utilization
R. Urban¹, J. S. Odorico², S. V. Niederhaus³, R. Carrico¹, A. Fox¹
¹United Network for Organ Sharing, Richmond, VA, ²Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, ³Department of Surgery, University of Maryland Medical Center, Baltimore, MD
*Purpose: In an effort to address the decline in pancreas transplantation, facilitated pancreas allocation (FPA) was modified August 16, 2016 from an opt-in system for…
2019 American Transplant Congress
A Safe Anti-A2 Titer for a Succesful A2 Incompatible Kidney Transplantation
G. Nair, M. Ajaimy, J. Graham, L. Liriano-Ward, A. Campbell, C. Pynadath, Y. Azzi, O. Andacoglu, S. Greenstein, M. Kinkhabwala, J. Rocca, E. Akalin
Montefiore Medical Center, Bronx, NY
*Purpose: The new kidney allocation system implemented in December 2014 allowed for use of A2/A2B donors to B recipients. However there is no mandate by…
2019 American Transplant Congress
Management of Anastomotic Biliary Strictures after Liver Transplant: Role of Covered Metal Stents
A. Watson¹, K. Haq¹, K. Khorfan², S. Singla¹, A. Yoshida³, D. Moonka¹
¹Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, ²Internal Medicine, Henry Ford Hospital, Detroit, MI, ³Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Biliary complications, including anastomotic biliary strictures (ABS), remain the most common cause of morbidity in liver transplant (LT) patients. Endoscopic therapy has become the…
2019 American Transplant Congress
Sub-Optimal Renal Recovery and Progressive Chronic Kidney Disease after Living Kidney Donation
Y. Kim¹, C. Jeong², H. Kim², J. Ha³, C. Ahn¹, Y. Kim¹, H. Lee¹
¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ²Department of Urology, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Post-operative renal recovery after nephrectomy is a substantial problem to be addressed in living kidney donors. Herein, we explored factors associated with renal recovery…
2019 American Transplant Congress
Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients
S. Sethi, A. Peng, R. Najjar, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Tocilizumab blocks IL-6 signaling, inhibiting maturation of B cells to plasma cells and antibody production. We have used tocilizumab since 2012 to treat kidney…
2019 American Transplant Congress
Regulating T Cell Responses by Forced Transgenic Expression of Decay-Accelerating Factor
D. Heja¹, Z. He¹, S. A. Lira¹, F. Lin², D. Homann¹, P. S. Heeger¹
¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Cleveland Clinic, Cleveland, OH
*Purpose: Decay-accelerating factor (DAF, CD55) is a cell surface expressed, glycophosphatidylinositol-(GPI)-anchored, complement regulator. Previous studies showed that during cognate T cell/antigen presenting cell (APC) interactions…
2019 American Transplant Congress
Factors Associated with Subclinical Cardiovascular Damage after Pediatric Liver Transplantation: A Longitudinal Observational Study
N. Memaran¹, I. Goldschmidt¹, B. Borchert¹, R. I. Sugianto¹, H. Wilke¹, R. Blöte¹, U. Baumann¹, E. Bauer¹, A. von Wick¹, N. Junge¹, C. Leiskau¹, E. D. Pfister¹, N. Richter², B. M. Schmidt³, A. Melk¹
¹Department of Pediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany, ²Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany, ³Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
*Purpose: Cardiovascular (CV) events account for 8-13% of deaths after liver transplantation (LT) in adulthood. While CV risk factors are present in children after LT…
2019 American Transplant Congress
Kidney Paired Donation Transplant Outcomes: Experiences from the First Ten Years of the National Kidney Registry
D. B. Leeser¹, A. G. Thomas², A. A. Shaffer², J. Veale³, A. B. Massie², M. Cooper⁴, S. Kapur⁵, S. Kapur⁵, S. Kapur⁵, N. Turgeon⁶, D. Segev², A. Waterman³, S. Flechner⁷
¹East Carolina Univ Sch of Med, Greenville, NC, ²Johns Hopkins, Baltimore, MD, ³UCLA, Los Angeles, CA, ⁴Georgetown, Washington, DC, ⁵Weill Cornell Medical School, New York, NY, ⁶Emory, Atlanta, GA, ⁷Cleveland Clinic, Cleveland, OH
*Purpose: In the United States (US), kidney paired donation (KPD) networks have facilitated an increasing proportion of KTs annually, but longer-term transplant outcomes and differences…